MiMedx Group Inc - Company Profile
Powered by 
All the data and insights you need on MiMedx Group Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date MiMedx Group Inc Strategy Report
- Understand MiMedx Group Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
MiMedx Group Inc (MiMedx) is a pharmaceutical company. It develops, manufactures and markets regenerative biologics utilizing human placental allografts. The company provides products such as amniotic membranes, umbilical cords, placental ECM and amniotic fluid. It utilizes a proprietary purion process that separates placental tissues, cleans and reassembles layers, and dehydrates the tissue to preserve the key elements associated with healing. MiMedx’s product delivers human extracellular matrix components for the regeneration of damaged or diseased tissues. Its products modulate inflammation, reduce scar tissue formation, and enhance healing. The company offers services in the areas of wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic and dental sectors of healthcare. MiMedx is headquartered in Marietta, Georgia, the US.
Headquarters
United States of America
Address
1775 W Oak Commons Court, Ne, Marietta, Georgia, 30062
Website
mimedx.com
Telephone
1 770 6519100
No of Employees
895
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MDXG (NASD)
Revenue (2023)
$321.5M
20%
(2023 vs 2022)
EPS
XYZ
Net Income (2023)
XYZ
292.8%
(2023 vs 2022)
Market Cap*
$1.2B
Net Profit Margin (2023)
XYZ
260.7%
(2023 vs 2022)
* As of and is in US$
MiMedx Group Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| EpiFix | EpiFix |
| EpiCord | |
| Epieffect | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In August, the company entered into an agreement with MediWound on EscharEx Phase III Study. |
| 2023 | Contracts/Agreements | In January, the company entered into a distribution agreement with Gunze Medical Limited for sales of EPIFIX in Japan. |
| 2022 | Contracts/Agreements | In December, the company entered into a licensing and distribution agreement with Turn Therapeutics to focus on wound and surgical recovery applications. |
Competitor Comparison
| Key Parameters | MiMedx Group Inc | Becton Dickinson and Co | DePuy Synthes Inc | Smith & Nephew Plc | Integra LifeSciences Holdings Corp |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United Kingdom | United States of America |
| City | Marietta | Franklin Lakes | Warsaw | Watford | Princeton |
| State/Province | Georgia | New Jersey | Indiana | England | New Jersey |
| No. of Employees | 895 | 73,000 | 18,000 | 18,452 | 3,946 |
| Entity Type | Public | Public | Private | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Kathleen Behrens, Ph.D. | Chairman | Executive Board | 2019 | 70 |
| Joseph H. Capper | Chief Executive Officer; Director | Executive Board | 2023 | 59 |
| Doug Rice | Chief Financial Officer | Senior Management | 2023 | - |
| Ricci S. Whitlow | Executive Vice President; Chief Operating Officer | Senior Management | 2022 | 55 |
| John Harper, Ph.D. | Chief Technology Officer; Senior Vice President - Research and Product Development | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer